Patents by Inventor Jan-Gerard Sterrenburg

Jan-Gerard Sterrenburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC BTK INHIBITORS
    Publication number: 20250074911
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of BTK (Bruton's Tyrosine Kinase). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment of Bruton's Tyrosine Kinase (BTK) mediated disorders, such as cancer.
    Type: Application
    Filed: December 14, 2022
    Publication date: March 6, 2025
    Applicant: Crossfire Oncology Holding B.V.
    Inventors: Adrianus Petrus Antonius de Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joeri Johannes Petrus de Wit, Freek van Cauter, Sander Petrus Wilhelmus van Gemert, Martine Berendina Wilhemina Prinsen, Winfried Robert Mulder, Michelle Muller, Diep Vu-Pham, Yvonne Grobben, Wilhelmina Elisabeth Simons-van Riel, Yvonne Gertruda Theodora Hendrika Van Mil
  • 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
    Publication number: 20230331729
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Application
    Filed: November 10, 2022
    Publication date: October 19, 2023
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C.A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C.H.M. Wijkmans
  • 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
    Publication number: 20210230166
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Application
    Filed: January 5, 2021
    Publication date: July 29, 2021
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C.A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C.H.M. Wijkmans
  • 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 11053230
    Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 6, 2021
    Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
  • 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
    Patent number: 10934296
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: March 2, 2021
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • Inhibitors of tryptophan 2,3-dioxygenase
    Patent number: 10689343
    Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: June 23, 2020
    Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
  • 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20200181128
    Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.
    Type: Application
    Filed: August 30, 2018
    Publication date: June 11, 2020
    Applicant: Netherlands Translational Research Center B.V.
    Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
  • Inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10494360
    Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: December 3, 2019
    Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V
    Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
  • INTIBTORS OF TRYPTOPHAN 2,3-DIOXYGENASE
    Publication number: 20190315688
    Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 17, 2019
    Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
  • 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
    Publication number: 20190276456
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Application
    Filed: February 14, 2019
    Publication date: September 12, 2019
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C.A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C.H.M. Wijkmans
  • 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
    Patent number: 10239883
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20190055213
    Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.
    Type: Application
    Filed: March 8, 2017
    Publication date: February 21, 2019
    Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius DE MAN, Joost Cornelis Marinus UITDEHAAG, Jan Gerard STERRENBURG, Joeri Johannes Petrus DE WIT, Nicole Wilhelmina Cornelia SEEGERS, Antonius Maria VAN DOORNMALEN, Rogier Christian BUIJSMAN, Guido Jenny Rudolf ZAMAN
  • 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
    Publication number: 20180179212
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 28, 2018
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C.A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C.H.M. Wijkmans
  • (5,6-dihydro)pyrimido[4,5-E]indolizines
    Patent number: 9856258
    Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 2, 2018
    Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman
  • 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors
    Patent number: 9790226
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: October 17, 2017
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
    Patent number: 9758524
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 12, 2017
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • BTK Inhibitors
    Patent number: 9718828
    Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: August 1, 2017
    Assignees: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.
    Inventors: Adrianus Petrus Antonius De Man, Jan-Gerard Sterrenburg, Hans C. A. Raaijmakers, Allard Kaptein, Arthur A. Oubrie, Johannes Bernardus Maria Rewinkel, Christiaan Gerardus Johannes Maria Jans, Jacobus C. H. M. Wijkmans, Tjeerd A. Barf, Alan B. Cooper, Ronald M. Kim, Sobhana Babu Boga, Hugh Y. Zhu, Xiaolei Gao, Xin Yao, Rajan Anand, Hao Wu, Shilan Liu, Chundao Yang, Abdul-Basit Alhassan, James Wang, Younong Yu, Jian Liu, Henry M. Vaccaro
  • (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES
    Publication number: 20170096432
    Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.
    Type: Application
    Filed: March 30, 2015
    Publication date: April 6, 2017
    Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius DE MAN, Rogier Christian BUIJSMAN, Jan Gerard STERRENBURG, Joost Cornelis Marinus UITDEHAAG, Joeri Johannes Petrus DE WIT, Guido Jenny Rudolf ZAMAN
  • (5,6-dihydro)pyrimido[4,5-E]indolizines
    Patent number: RE48974
    Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 15, 2022
    Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman
  • (5,6-dihydro)pyrimido[4,5-e]indolizines
    Patent number: RE50082
    Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: August 20, 2024
    Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.
    Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman